These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29912583)

  • 1. Pixantrone: novel mode of action and clinical readouts.
    Minotti G; Han H; Cattan V; Egorov A; Bertoni F
    Expert Rev Hematol; 2018 Jul; 11(7):587-596. PubMed ID: 29912583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma.
    Jamal-Hanjani M; Pettengell R
    Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1441-8. PubMed ID: 21905966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pixantrone beyond monotherapy: a review.
    Barrenetxea Lekue C; Grasso Cicala S; Leppä S; Stauffer Larsen T; Herráez Rodríguez S; Alonso Caballero C; Jørgensen JM; Toldbod H; Leal Martínez I; D'Amore F
    Ann Hematol; 2019 Sep; 98(9):2025-2033. PubMed ID: 31312929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rethinking Drugs from Chemistry to Therapeutic Opportunities: Pixantrone beyond Anthracyclines.
    Menna P; Salvatorelli E; Minotti G
    Chem Res Toxicol; 2016 Aug; 29(8):1270-8. PubMed ID: 27420111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pixantrone maleate for non-Hodgkin's lymphoma.
    Mukherji D; Pettengell R
    Drugs Today (Barc); 2009 Nov; 45(11):797-805. PubMed ID: 20126672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pixantrone for the treatment of aggressive non-Hodgkin lymphoma.
    Mukherji D; Pettengell R
    Expert Opin Pharmacother; 2010 Aug; 11(11):1915-23. PubMed ID: 20569087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients.
    Salvatorelli E; Menna P; Paz OG; Chello M; Covino E; Singer JW; Minotti G
    J Pharmacol Exp Ther; 2013 Feb; 344(2):467-78. PubMed ID: 23192654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and Safety of Pixantrone for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Every-Day Clinical Practice: The Italian Cohort of the PIXA Registry.
    Zinzani PL; Bregni M; Spione M; Mitterer M; Musuraca G; Bugli A; Piazza F; Pinto A
    Acta Haematol; 2021; 144(3):259-263. PubMed ID: 33040061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma.
    Hübel K
    Expert Opin Pharmacother; 2018 Nov; 19(16):1829-1834. PubMed ID: 30269614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of pixantrone in the treatment of non-Hodgkin's lymphoma.
    Borchmann P; Schnell R
    Expert Opin Investig Drugs; 2005 Aug; 14(8):1055-61. PubMed ID: 16050797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pixantrone: a novel aza-anthracenedione in the treatment of non-Hodgkin's lymphomas.
    El-Helw LM; Hancock BW
    Expert Opin Investig Drugs; 2007 Oct; 16(10):1683-91. PubMed ID: 17922631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial.
    Pettengell R; Coiffier B; Narayanan G; de Mendoza FH; Digumarti R; Gomez H; Zinzani PL; Schiller G; Rizzieri D; Boland G; Cernohous P; Wang L; Kuepfer C; Gorbatchevsky I; Singer JW
    Lancet Oncol; 2012 Jul; 13(7):696-706. PubMed ID: 22652183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma.
    Boyle EM; Morschhauser F
    Expert Opin Drug Saf; 2015 Apr; 14(4):601-7. PubMed ID: 25716061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas.
    Sancho JM; Navarro B; Soler Campos JA; de Oteyza JP; de Barrenetxea Lekue C; Bregni M; Grasso Cicala S; Spione M; Mombiedro C; Soler B; Zinzani PL
    Eur J Haematol; 2020 May; 104(5):499-508. PubMed ID: 31997425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma.
    Keating GM
    Drugs; 2016 Oct; 76(16):1579-1586. PubMed ID: 27757832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma.
    Eyre TA; Linton KM; Rohman P; Kothari J; Cwynarski K; Ardeshna K; Bailey C; Osborne WL; Rowntree C; Eden D; Shankara P; Eyre DW; Jasani P; Chaidos A; Collins GP; Hatton CS
    Br J Haematol; 2016 Jun; 173(6):896-904. PubMed ID: 26956150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Cost-effectiveness of Pixantrone for Third/Fourth-line Treatment of Aggressive Non-Hodgkin's Lymphoma.
    Muszbek N; Kadambi A; Lanitis T; Hatswell AJ; Patel D; Wang L; Singer JW; Pettengell R
    Clin Ther; 2016 Mar; 38(3):503-15. PubMed ID: 26856929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.
    Hasinoff BB; Wu X; Patel D; Kanagasabai R; Karmahapatra S; Yalowich JC
    J Pharmacol Exp Ther; 2016 Feb; 356(2):397-409. PubMed ID: 26660439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone.
    Cavalletti E; Crippa L; Mainardi P; Oggioni N; Cavagnoli R; Bellini O; Sala F
    Invest New Drugs; 2007 Jun; 25(3):187-95. PubMed ID: 17285358
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.